Sponsor Pipeline

Shanghai Escugen Biotechnology Co., Ltd Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
4
Active Trials
2
Recruiting
1
Disease Areas
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-08-12 NCT07760155 A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody… Phase 2 Not Yet Recruiting
Active Trials by Phase
Phase 2
2
Phase 1/2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT07375524 A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody… Primary Sjögren Syndrome Not Yet Recruiting
NCT07760155 A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody… Systemic Lupus Erythematosus (SLE) Not Yet Recruiting
Phase 1/2
NCT06853444 A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia Immune Thrombocytopenia (ITP) Recruiting
Phase 1
NCT06979674 Study of ESG406 in Adults With Solid Tumors Locally Advanced/Metastatic Solid Tumors Recruiting
Disease Areas
Lupus (SLE) (1)
Get alerts when Shanghai Escugen Biotechnology Co., Ltd's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free